Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study.

Rosenberg LU, Granath F, Dickman PW, Einarsdóttir K, Wedrén S, Persson I, Hall P.

Breast Cancer Res. 2008;10(5):R78. doi: 10.1186/bcr2145.

2.
3.

Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.

Glass AG, Lacey JV Jr, Carreon JD, Hoover RN.

J Natl Cancer Inst. 2007 Aug 1;99(15):1152-61.

PMID:
17652280
4.

Menopausal hormone therapy and risk of clinical breast cancer subtypes.

Slanger TE, Chang-Claude JC, Obi N, Kropp S, Berger J, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Flesch-Janys D.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1188-96. doi: 10.1158/1055-9965.EPI-09-0002.

5.

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R.

JAMA. 2000 Jan 26;283(4):485-91. Erratum in: JAMA 2000 Nov 22-29;284(20):2597.

PMID:
10659874
6.

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S, Newcomb PA, Prentice RL.

J Natl Cancer Inst. 2013 Apr 17;105(8):526-35. doi: 10.1093/jnci/djt043.

7.

[Hormone replacement therapy in menopause and risk of breast cancer].

Clavel-Chapelon F, Hill C.

Presse Med. 2000 Oct 21;29(31):1688-93. Review. French.

PMID:
11094609
8.

Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort.

Obi N, Heinz J, Seibold P, Vrieling A, Rudolph A, Chang-Claude J, Berger J, Flesch-Janys D.

Int J Cancer. 2016 May 1;138(9):2098-108. doi: 10.1002/ijc.29951.

PMID:
26649645
9.

Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?

Ursin G, Tseng CC, Paganini-Hill A, Enger S, Wan PC, Formenti S, Pike MC, Ross RK.

J Clin Oncol. 2002 Feb 1;20(3):699-706.

PMID:
11821451
11.

Postmenopausal estrogen and progestin use in relation to breast cancer risk.

Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ.

Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):593-600.

12.

Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer.

Reding KW, Doody DR, McTiernan A, Hsu L, Davis S, Daling JR, Porter PL, Malone KE.

Breast Cancer Res Treat. 2011 Apr;126(3):749-61. doi: 10.1007/s10549-010-1174-7.

13.
14.

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE.

N Engl J Med. 1995 Jun 15;332(24):1589-93.

15.

Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.

Li CI, Daling JR, Haugen KL, Tang MT, Porter PL, Malone KE.

Breast Cancer Res Treat. 2014 Jun;145(2):481-9. doi: 10.1007/s10549-014-2960-4.

16.

Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.

Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA.

J Clin Oncol. 2003 Dec 1;21(23):4314-21.

PMID:
14645420
17.
18.

Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis.

Reeves GK, Beral V, Green J, Gathani T, Bull D; Million Women Study Collaborators..

Lancet Oncol. 2006 Nov;7(11):910-8.

PMID:
17081916
19.

Hormone replacement therapy and cancer.

[No authors listed]

Gynecol Endocrinol. 2001 Dec;15(6):453-65. Review.

PMID:
11826770
20.

Interaction between current vitamin D supplementation and menopausal hormone therapy use on breast cancer risk: evidence from the E3N cohort.

Cadeau C, Fournier A, Mesrine S, Clavel-Chapelon F, Fagherazzi G, Boutron-Ruault MC.

Am J Clin Nutr. 2015 Oct;102(4):966-73. doi: 10.3945/ajcn.114.104323.

Supplemental Content

Support Center